Successful treatment of adult Langerhans cell histiocytosis with intensified chemotherapy

Mariko Minami, Takahiro Shima, Koji Kato, Hidetaka Yamamoto, Kenji Tsuchihashi, Seido Oku, Tomonori Shimokawa, Taro Tochigi, Goichi Yoshimoto, Kenjiro Kamezaki, Katsuto Takenaka, Hiromi Iwasaki, Yoshinao Oda, Toshihiro Miyamoto, Koichi Akashi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Langerhans cell histiocytosis (LCH) is a rare disease in adults. The treatment strategy for this condition remains controversial. Intensified systemic chemotherapy is required in pediatric patients with the multiple system form of LCH (MS-LCH) for aggressive forms of the disease. Recent clinical trials have shown that intensified chemotherapy for pediatric patients diagnosed with MS-LCH results in improved outcomes. However, whether the feasibility and efficacy of an intensified systemic chemotherapy regimen are also beneficial for adult patients with MS-LCH remains unclear. Here, we report two cases of adult MS-LCH that were successfully treated with an intensified treatment protocol as used in pediatric patients. One patient fully completed the protocol, and has since maintained a complete response (CR) for 2 years following completion of the treatment. The other patient also achieved CR after induction therapy, and is now undergoing maintenance therapy in an outpatient clinic. The cases presented in this study suggest that intensified systemic chemotherapy as used for pediatric patients with MS-LCH is well tolerated and effective for adult patients as well.

Original languageEnglish
Pages (from-to)244-248
Number of pages5
JournalInternational journal of hematology
Volume102
Issue number2
DOIs
Publication statusPublished - Aug 11 2015

Fingerprint

Langerhans Cell Histiocytosis
Drug Therapy
Pediatrics
Therapeutics
Clinical Protocols
Rare Diseases
Ambulatory Care Facilities
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Successful treatment of adult Langerhans cell histiocytosis with intensified chemotherapy. / Minami, Mariko; Shima, Takahiro; Kato, Koji; Yamamoto, Hidetaka; Tsuchihashi, Kenji; Oku, Seido; Shimokawa, Tomonori; Tochigi, Taro; Yoshimoto, Goichi; Kamezaki, Kenjiro; Takenaka, Katsuto; Iwasaki, Hiromi; Oda, Yoshinao; Miyamoto, Toshihiro; Akashi, Koichi.

In: International journal of hematology, Vol. 102, No. 2, 11.08.2015, p. 244-248.

Research output: Contribution to journalArticle

@article{1962c9ffac22467ab51d0d06a4680e90,
title = "Successful treatment of adult Langerhans cell histiocytosis with intensified chemotherapy",
abstract = "Langerhans cell histiocytosis (LCH) is a rare disease in adults. The treatment strategy for this condition remains controversial. Intensified systemic chemotherapy is required in pediatric patients with the multiple system form of LCH (MS-LCH) for aggressive forms of the disease. Recent clinical trials have shown that intensified chemotherapy for pediatric patients diagnosed with MS-LCH results in improved outcomes. However, whether the feasibility and efficacy of an intensified systemic chemotherapy regimen are also beneficial for adult patients with MS-LCH remains unclear. Here, we report two cases of adult MS-LCH that were successfully treated with an intensified treatment protocol as used in pediatric patients. One patient fully completed the protocol, and has since maintained a complete response (CR) for 2 years following completion of the treatment. The other patient also achieved CR after induction therapy, and is now undergoing maintenance therapy in an outpatient clinic. The cases presented in this study suggest that intensified systemic chemotherapy as used for pediatric patients with MS-LCH is well tolerated and effective for adult patients as well.",
author = "Mariko Minami and Takahiro Shima and Koji Kato and Hidetaka Yamamoto and Kenji Tsuchihashi and Seido Oku and Tomonori Shimokawa and Taro Tochigi and Goichi Yoshimoto and Kenjiro Kamezaki and Katsuto Takenaka and Hiromi Iwasaki and Yoshinao Oda and Toshihiro Miyamoto and Koichi Akashi",
year = "2015",
month = "8",
day = "11",
doi = "10.1007/s12185-015-1778-0",
language = "English",
volume = "102",
pages = "244--248",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Successful treatment of adult Langerhans cell histiocytosis with intensified chemotherapy

AU - Minami, Mariko

AU - Shima, Takahiro

AU - Kato, Koji

AU - Yamamoto, Hidetaka

AU - Tsuchihashi, Kenji

AU - Oku, Seido

AU - Shimokawa, Tomonori

AU - Tochigi, Taro

AU - Yoshimoto, Goichi

AU - Kamezaki, Kenjiro

AU - Takenaka, Katsuto

AU - Iwasaki, Hiromi

AU - Oda, Yoshinao

AU - Miyamoto, Toshihiro

AU - Akashi, Koichi

PY - 2015/8/11

Y1 - 2015/8/11

N2 - Langerhans cell histiocytosis (LCH) is a rare disease in adults. The treatment strategy for this condition remains controversial. Intensified systemic chemotherapy is required in pediatric patients with the multiple system form of LCH (MS-LCH) for aggressive forms of the disease. Recent clinical trials have shown that intensified chemotherapy for pediatric patients diagnosed with MS-LCH results in improved outcomes. However, whether the feasibility and efficacy of an intensified systemic chemotherapy regimen are also beneficial for adult patients with MS-LCH remains unclear. Here, we report two cases of adult MS-LCH that were successfully treated with an intensified treatment protocol as used in pediatric patients. One patient fully completed the protocol, and has since maintained a complete response (CR) for 2 years following completion of the treatment. The other patient also achieved CR after induction therapy, and is now undergoing maintenance therapy in an outpatient clinic. The cases presented in this study suggest that intensified systemic chemotherapy as used for pediatric patients with MS-LCH is well tolerated and effective for adult patients as well.

AB - Langerhans cell histiocytosis (LCH) is a rare disease in adults. The treatment strategy for this condition remains controversial. Intensified systemic chemotherapy is required in pediatric patients with the multiple system form of LCH (MS-LCH) for aggressive forms of the disease. Recent clinical trials have shown that intensified chemotherapy for pediatric patients diagnosed with MS-LCH results in improved outcomes. However, whether the feasibility and efficacy of an intensified systemic chemotherapy regimen are also beneficial for adult patients with MS-LCH remains unclear. Here, we report two cases of adult MS-LCH that were successfully treated with an intensified treatment protocol as used in pediatric patients. One patient fully completed the protocol, and has since maintained a complete response (CR) for 2 years following completion of the treatment. The other patient also achieved CR after induction therapy, and is now undergoing maintenance therapy in an outpatient clinic. The cases presented in this study suggest that intensified systemic chemotherapy as used for pediatric patients with MS-LCH is well tolerated and effective for adult patients as well.

UR - http://www.scopus.com/inward/record.url?scp=84938983257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938983257&partnerID=8YFLogxK

U2 - 10.1007/s12185-015-1778-0

DO - 10.1007/s12185-015-1778-0

M3 - Article

C2 - 25753226

AN - SCOPUS:84938983257

VL - 102

SP - 244

EP - 248

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 2

ER -